Tumor-associated Carbohydrate Antigen

Tumor-associated carbohydrate antigens (TACAs) are specific carbohydrate structures that are aberrantly expressed on the surface of cancer cells, distinguishing them from normal tissues. These antigens arise due to altered glycosylation patterns in malignant cells and can be found on both glycoproteins and glycolipids. TACAs serve as molecular markers for tumor identification and play significant roles in tumor biology, including influencing cell signaling, metastasis, immune evasion, angiogenesis, apoptosis, motility, and cell adhesion. Their restricted expression profile makes them valuable diagnostic markers and promising therapeutic targets across multiple modalities—including monoclonal antibodies, CAR-based cellular therapies, bispecific constructs, and next-generation anticancer vaccines—with ongoing research focused on overcoming their inherent low immunogenicity while maximizing anti-tumor efficacy.

Other names

TACACA19-9 (Sialyl Lewis A)GD2MUC1Sialyl-TnThomsen-Friedenreich antigen

Monoclonal antibodies inducing direct cytotoxicity; CAR-T/CAR-NK/CAR-Macrophage therapies engineered against specific TACA epitopes; Bispecific antibodies engaging both immune effector cells and tumor-specific carbohydrates.